NeoRecormon

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
15-03-2023
Toote omadused Toote omadused (SPC)
15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
03-12-2015

Toimeaine:

epoetin beta

Saadav alates:

Roche Registration GmbH

ATC kood:

B03XA01

INN (Rahvusvaheline Nimetus):

epoetin beta

Terapeutiline rühm:

Antianemic preparations

Terapeutiline ala:

Kidney Failure, Chronic; Anemia; Cancer; Blood Transfusion, Autologous

Näidustused:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).

Toote kokkuvõte:

Revision: 33

Volitamisolek:

Authorised

Loa andmise kuupäev:

1997-07-16

Infovoldik

                                48
B. PACKAGE LEAFLET
49
PACKAGE LEAFLET: INFORMATION FOR THE USER
NEORECORMON 500 IU
NEORECORMON 2000 IU
NEORECORMON 3000 IU
NEORECORMON 4000 IU
NEORECORMON 5000 IU
NEORECORMON 6000 IU
NEORECORMON 10,000 IU
NEORECORMON 20,000 IU
NEORECORMON 30,000 IU
SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
epoetin beta
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs or illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What NeoRecormon is and what it is used for
2.
What you need to know before you use NeoRecormon
3.
How to use NeoRecormon
4.
Possible side effects
5.
How to store NeoRecormon
6.
Content of the pack and other information
1.
WHAT NEORECORMON IS AND WHAT IT IS USED FOR
NeoRecormon is a clear, colourless solution for injection under the
skin
_(subcutaneously)_
or into a
vein
_(intravenously). _
It contains a hormone called
_epoetin beta_
, which stimulates the production of red
blood cells. Epoetin beta is produced by a specialised genetic
technology and works in exactly the
same way as the natural hormone erythropoietin.
You must talk to your doctor if you do not feel better or if you feel
worse.
NeoRecormon is indicated for:
•
TREATING SYMPTOMATIC ANAEMIA CAUSED BY CHRONIC KIDNEY DISEASE
(renal anaemia) in patients
on dialysis, or not yet on dialysis.
•
PREVENTING ANAEMIA IN PREMATURE INFANTS
(weighing 750 to 1500 g and born at less than
34 weeks).
•
TREATING ANAEMIA WITH RELATED SYMPTOMS IN ADULT CANCER PATIENTS
RECEIVING CHEMOTHERAPY
•
TREATING PEOPLE DONATING THEIR OWN BLOOD BEFORE SURGERY.
The injections of epoetin beta will
increas
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
NeoRecormon 500 IU solution for injection in pre-filled syringe
NeoRecormon 2000 IU solution for injection in pre-filled syringe
NeoRecormon 3000 IU solution for injection in pre-filled syringe
NeoRecormon 4000 IU solution for injection in pre-filled syringe
NeoRecormon 5000 IU solution for injection in pre-filled syringe
NeoRecormon 6000 IU solution for injection in pre-filled syringe
NeoRecormon 10,000 IU solution for injection in pre-filled syringe
NeoRecormon 20,000 IU solution for injection in pre-filled syringe
NeoRecormon 30,000 IU solution for injection in pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
NeoRecormon 500 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains 500
international units (IU)
corresponding to 4.15 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 1667 IU epoetin beta.
NeoRecormon 2000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
2000 international units (IU)
corresponding to 16.6 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 6667 IU epoetin beta.
NeoRecormon 3000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
3000 international units (IU)
corresponding to 24.9 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 10,000 IU epoetin beta.
NeoRecormon 4000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
4000 international units (IU)
corresponding to 33.2 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 13,333 IU epoetin beta.
NeoRecormon 5000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 15-03-2023
Toote omadused Toote omadused bulgaaria 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 03-12-2015
Infovoldik Infovoldik hispaania 15-03-2023
Toote omadused Toote omadused hispaania 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 03-12-2015
Infovoldik Infovoldik tšehhi 15-03-2023
Toote omadused Toote omadused tšehhi 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 03-12-2015
Infovoldik Infovoldik taani 15-03-2023
Toote omadused Toote omadused taani 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande taani 03-12-2015
Infovoldik Infovoldik saksa 15-03-2023
Toote omadused Toote omadused saksa 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande saksa 03-12-2015
Infovoldik Infovoldik eesti 15-03-2023
Toote omadused Toote omadused eesti 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande eesti 03-12-2015
Infovoldik Infovoldik kreeka 15-03-2023
Toote omadused Toote omadused kreeka 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 03-12-2015
Infovoldik Infovoldik prantsuse 15-03-2023
Toote omadused Toote omadused prantsuse 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 03-12-2015
Infovoldik Infovoldik itaalia 15-03-2023
Toote omadused Toote omadused itaalia 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 03-12-2015
Infovoldik Infovoldik läti 15-03-2023
Toote omadused Toote omadused läti 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande läti 03-12-2015
Infovoldik Infovoldik leedu 15-03-2023
Toote omadused Toote omadused leedu 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande leedu 03-12-2015
Infovoldik Infovoldik ungari 15-03-2023
Toote omadused Toote omadused ungari 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande ungari 03-12-2015
Infovoldik Infovoldik malta 15-03-2023
Toote omadused Toote omadused malta 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande malta 03-12-2015
Infovoldik Infovoldik hollandi 15-03-2023
Toote omadused Toote omadused hollandi 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 03-12-2015
Infovoldik Infovoldik poola 15-03-2023
Toote omadused Toote omadused poola 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande poola 03-12-2015
Infovoldik Infovoldik portugali 15-03-2023
Toote omadused Toote omadused portugali 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande portugali 03-12-2015
Infovoldik Infovoldik rumeenia 15-03-2023
Toote omadused Toote omadused rumeenia 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 03-12-2015
Infovoldik Infovoldik slovaki 15-03-2023
Toote omadused Toote omadused slovaki 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 03-12-2015
Infovoldik Infovoldik sloveeni 15-03-2023
Toote omadused Toote omadused sloveeni 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 03-12-2015
Infovoldik Infovoldik soome 15-03-2023
Toote omadused Toote omadused soome 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande soome 03-12-2015
Infovoldik Infovoldik rootsi 15-03-2023
Toote omadused Toote omadused rootsi 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 03-12-2015
Infovoldik Infovoldik norra 15-03-2023
Toote omadused Toote omadused norra 15-03-2023
Infovoldik Infovoldik islandi 15-03-2023
Toote omadused Toote omadused islandi 15-03-2023
Infovoldik Infovoldik horvaadi 15-03-2023
Toote omadused Toote omadused horvaadi 15-03-2023
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 03-12-2015

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu